TORONTO, November 10, 2025 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABORATORIES) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company focused on precision cannabinoids, is pleased to announce that it will report third quarter financial results for the three and nine months ended September 30th.th2025, before markets open on Thursday 13 November.th2025.
MediPharm Labs executive management will also host a conference call and webcast on Thursday, November 13th.th2025 at 10:00 a.m. (ET) to discuss the company's financial results.
Conference call details:
Toll free in North America: (888) 330-2454.
International call: +1 (240) 789-2714
Conference number: 4921762
Participants are asked to dial approximately 15 minutes before the start of the call.
Webcast:
The online broadcast will be available at the following link. Here.
For those unable to attend the live call or webcast, a replay will be available at: https://www.medipharmlabs.com/investors about a day after the call ended.
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the development and production of pharmaceutical grade purified cannabis concentrates, active pharmaceutical ingredients (APIs) and advanced derivative products in a GMP certified facility and ISO cleanrooms. MediPharm Labs has invested in an expert, research-based team, state-of-the-art technology, post-purification methodologies and purpose-built facilities to deliver pure, reliable and precisely dosed cannabis products to its customers. MediPharm Labs designs, develops, processes, packages and distributes cannabis and advanced cannabinoid products to domestic and international medical markets.
In 2021, MediPharm Labs received a pharmaceutical manufacturing license from Health Canada, becoming the only company in North America with a domestic commercial-scale Good Manufacturing Practices license to extract multiple naturally occurring cannabinoids. This GMP license was the first step in registering the company's current overseas drug manufacturing facility with the US FDA.
In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm's reach to medical patients in Canada through the medical e-commerce platform Canna Farms, and in Australia and Germany through Beacon Medical PTY and Beacon Medical GMBH. The acquisition also included Harvest Medical Clinics in Canada, which provides medical cannabis patients with physician consultations for medical cannabis education and prescriptions.
The Company operates in compliance with all applicable laws of the countries in which it operates.
Website: www.medipharmlabs.com
Cautionary Note Regarding Forward-Looking Information
This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as of the date of this press release. Any statement that includes a discussion of projections, expectations, beliefs, plans, projections, goals, assumptions, future events or results (often, but not always, using phrases such as “expects” or “does not expect,” “expects,” “anticipates” or “does not anticipate,” “plans,” “budget,” “scheduled,” “predicts,” “estimates,” “believes,” or “intends,” or variations of such words and phrases, or states that certain actions, events or results “may” or “could”, “might” or “will” occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this press release, forward-looking statements relate to, among other things, statements regarding the release of MediPharm's financial results and the future registration of MediPharm's foreign drug manufacturing facility. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while believed to be reasonable, are subject to known and unknown risks, uncertainties and other factors that may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; MediPharm's inability to obtain adequate financing; delay or failure to obtain regulatory approvals; and other factors discussed in MediPharm's filings available on SEDAR+ at: www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Except as required by law, MediPharm does not undertake any obligation to update forward-looking statements, beliefs, opinions, forecasts or other factors if they change.
SOURCE MediPharm Labs Corp.
For more information, please contact: MediPharm Labs Investor Relations,
1 416.913.7425, [email protected]
